Our biosimilar production line is a fully integrated manufacturing system tailored for the end-to-end production of biosimilar drugs. Compliant with global GMP and relevant regulatory guidelines, it covers upstream cell culture, downstream purification, formulation and aseptic fill-finish. The line features precise process parameter control, stable mass transfer and scalable design, ensuring high consistency in product quality, efficacy and safety compared with reference products. Adopting hygienic construction, automated operation, CIP/SIP and complete data traceability, it minimizes operational risks and simplifies regulatory validation. Flexible layout and modular configuration adapt to multiple product varieties and production capacities, an ideal solution for pilot trials and large-scale commercial manufacturing of biosimilars.
